tazobactam ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
beta-lactamase inhibitors 2572 89786-04-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • tazobactam
  • tazobactam sodium
  • YTR-830
  • YTR 830
A penicillanic acid and sulfone derivative and potent BETA-LACTAMASE inhibitor that enhances the activity of other anti-bacterial agents against beta-lactamase producing bacteria.
  • Molecular weight: 300.29
  • Formula: C10H12N4O5S
  • CLOGP: -0.65
  • LIPINSKI: 0
  • HAC: 9
  • HDO: 1
  • TPSA: 122.46
  • ALOGS: -1.50
  • ROTB: 3

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 50 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 77 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 66.49 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 0.26 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 4.81 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.70 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 0.97 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Oct. 22, 1993 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Thrombocytopenia 105.21 18.96 114 7794 127559 50469657
Sepsis 75.19 18.96 98 7810 132827 50464389
Pyrexia 66.79 18.96 168 7740 380035 50217181
Acute kidney injury 65.49 18.96 123 7785 227935 50369281
Respiratory failure 59.10 18.96 72 7836 91109 50506107
Eosinophilia 54.98 18.96 35 7873 18617 50578599
Multiple organ dysfunction syndrome 54.20 18.96 52 7856 50285 50546931
Pancytopenia 53.88 18.96 66 7842 83964 50513252
Leukopenia 51.53 18.96 58 7850 67470 50529746
Renal failure 50.23 18.96 72 7836 106561 50490655
Toxic epidermal necrolysis 48.85 18.96 34 7874 20958 50576258
Dermatitis exfoliative generalised 47.43 18.96 18 7890 3108 50594108
Septic shock 45.15 18.96 50 7858 57125 50540091
Rash maculo-papular 43.74 18.96 35 7873 26606 50570610
Disseminated intravascular coagulation 40.44 18.96 28 7880 17107 50580109
Platelet count decreased 38.87 18.96 62 7846 100664 50496552
Tubulointerstitial nephritis 38.61 18.96 26 7882 15185 50582031
Rash morbilliform 34.75 18.96 14 7894 2832 50594384
Arthralgia 34.14 18.96 13 7895 438689 50158527
Haemoglobin decreased 32.01 18.96 65 7843 127151 50470065
Pleural effusion 31.23 18.96 50 7858 81404 50515812
Heparin-induced thrombocytopenia 30.28 18.96 14 7894 3951 50593265
Fatigue 30.22 18.96 40 7868 707561 49889655
Drug reaction with eosinophilia and systemic symptoms 29.89 18.96 29 7879 28395 50568821
Agranulocytosis 28.64 18.96 25 7883 21396 50575820
Nephropathy toxic 28.58 18.96 17 7891 8012 50589204
Toxic skin eruption 28 18.96 19 7889 11232 50585984
Pseudomonal sepsis 27.93 18.96 11 7897 2096 50595120
Drug ineffective 26.90 18.96 55 7853 819278 49777938
Acute generalised exanthematous pustulosis 26.90 18.96 17 7891 8921 50588295
Linear IgA disease 25.64 18.96 9 7899 1245 50595971
Joint swelling 25.37 18.96 4 7904 245282 50351934
Prothrombin time prolonged 24.59 18.96 16 7892 8822 50588394
Headache 24.39 18.96 26 7882 506509 50090707
Drug intolerance 24.00 18.96 3 7905 219101 50378115
Platelet count increased 23.64 18.96 19 7889 14521 50582695
Alopecia 23.18 18.96 5 7903 245042 50352174
Aspergillus infection 23.13 18.96 14 7894 6807 50590409
White blood cell count decreased 22.93 18.96 54 7854 116668 50480548
Fall 22.77 18.96 12 7896 334920 50262296
Neutropenia 22.37 18.96 62 7846 147903 50449313
Leukocytosis 21.81 18.96 22 7886 22557 50574659
Blood creatinine increased 21.67 18.96 41 7867 76119 50521097
Haemolytic anaemia 21.49 18.96 15 7893 9277 50587939
Abdominal discomfort 21.36 18.96 5 7903 231636 50365580
Dizziness 21.30 18.96 14 7894 346355 50250861
Hypokalaemia 20.99 18.96 44 7864 87948 50509268
Acinetobacter infection 20.87 18.96 8 7900 1419 50595797
Stevens-Johnson syndrome 20.66 18.96 21 7887 21731 50575485
Product contamination microbial 20.17 18.96 5 7903 205 50597011
Febrile neutropenia 20.07 18.96 46 7862 97621 50499595
Brain oedema 19.76 18.96 16 7892 12354 50584862
Streptococcal infection 19.41 18.96 11 7897 4737 50592479
Anaemia 19.06 18.96 84 7824 252372 50344844

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Tubulointerstitial nephritis 96.68 17.12 66 10290 17577 29546594
Acute kidney injury 95.67 17.12 254 10102 265013 29299158
Thrombocytopenia 84.35 17.12 161 10195 134662 29429509
Sepsis 79.14 17.12 162 10194 142520 29421651
Pyrexia 69.19 17.12 239 10117 287383 29276788
Lymphocyte count abnormal 65.99 17.12 19 10337 608 29563563
Multiple organ dysfunction syndrome 58.70 17.12 90 10266 63026 29501145
Clostridial infection 46.87 17.12 23 10333 3292 29560879
Platelet count decreased 44.53 17.12 107 10249 104565 29459606
Disseminated intravascular coagulation 43.97 17.12 44 10312 19936 29544235
Agranulocytosis 41.50 17.12 43 10313 20297 29543874
Renal tubular necrosis 40.04 17.12 36 10320 14279 29549892
Rash 39.72 17.12 151 10205 189668 29374503
Stevens-Johnson syndrome 39.41 17.12 38 10318 16459 29547712
Septic shock 39.35 17.12 75 10281 62485 29501686
Neutropenia 38.28 17.12 117 10239 131594 29432577
Drug reaction with eosinophilia and systemic symptoms 38.13 17.12 48 10308 27944 29536227
Dizziness 35.79 17.12 11 10345 189673 29374498
Cholestasis 34.80 17.12 42 10314 23420 29540751
Choroiditis 34.50 17.12 13 10343 975 29563196
Respiratory failure 32.73 17.12 91 10265 97040 29467131
Nephropathy toxic 31.97 17.12 28 10328 10728 29553443
Renal failure 31.36 17.12 102 10254 118497 29445674
Clostridium difficile colitis 30.74 17.12 30 10326 13182 29550989
Heparin-induced thrombocytopenia 30.56 17.12 20 10336 4959 29559212
Congenital pneumonia 29.98 17.12 7 10349 95 29564076
Blood creatinine increased 29.92 17.12 81 10275 85021 29479150
Eosinophilia 25.52 17.12 35 10321 22126 29542045
Pneumonia staphylococcal 24.28 17.12 14 10342 2771 29561400
Fatigue 23.77 17.12 47 10309 316774 29247397
Transplant rejection 23.48 17.12 22 10334 9190 29554981
Alanine aminotransferase increased 23.41 17.12 66 10290 70878 29493293
Subclavian artery occlusion 23.38 17.12 6 10350 123 29564048
Neutrophil count increased 22.86 17.12 27 10329 14715 29549456
Spontaneous haematoma 22.80 17.12 8 10348 489 29563682
Hepatic failure 22.59 17.12 40 10316 31472 29532699
Chills 22.24 17.12 65 10291 71235 29492936
Aspartate aminotransferase increased 22.14 17.12 58 10298 59667 29504504
Haemodialysis 22.04 17.12 22 10334 9932 29554239
Leukopenia 21.90 17.12 55 10301 55148 29509023
Blood alkaline phosphatase increased 21.59 17.12 37 10319 28369 29535802
Dialysis 21.57 17.12 22 10334 10186 29553985
Pancytopenia 21.48 17.12 71 10285 83097 29481074
Lymphocyte count 21.48 17.12 5 10351 67 29564104
Death 21.41 17.12 56 10300 342028 29222143
Headache 21.07 17.12 18 10338 173989 29390182
Rash erythematous 20.36 17.12 31 10325 21531 29542640
Organ failure 20.34 17.12 11 10345 1925 29562246
Acute respiratory distress syndrome 20.30 17.12 32 10324 22903 29541268
Autoimmune haemolytic anaemia 20.13 17.12 14 10342 3834 29560337
Drug eruption 20.12 17.12 27 10329 16714 29547457
Hepatic function abnormal 19.82 17.12 43 10313 39216 29524955
Blood bilirubin increased 19.30 17.12 39 10317 33854 29530317
Gamma-glutamyltransferase increased 19.24 17.12 34 10322 26703 29537468
Rash maculo-papular 18.93 17.12 32 10324 24257 29539914
Anaphylactic reaction 18.49 17.12 34 10322 27539 29536632
Respiratory distress 18.35 17.12 37 10319 32069 29532102
Dermatitis exfoliative 17.65 17.12 16 10340 6409 29557762
Intraocular pressure increased 17.39 17.12 14 10342 4775 29559396

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Acute kidney injury 153.04 16.76 327 14621 448913 64034871
Thrombocytopenia 137.79 16.76 211 14737 223590 64260194
Tubulointerstitial nephritis 122.81 16.76 81 14867 30828 64452956
Sepsis 114.30 16.76 197 14751 230144 64253640
Pyrexia 94.81 16.76 314 14634 558330 63925454
Multiple organ dysfunction syndrome 81.98 16.76 109 14839 101304 64382480
Septic shock 81.68 16.76 111 14837 105326 64378458
Renal failure 78.00 16.76 146 14802 181542 64302242
Eosinophilia 73.73 16.76 65 14883 38011 64445773
Drug reaction with eosinophilia and systemic symptoms 66.38 16.76 72 14876 54145 64429639
Clostridial infection 61.73 16.76 28 14920 5091 64478693
Fatigue 59.36 16.76 52 14896 748678 63735106
Rash maculo-papular 58.52 16.76 63 14885 46963 64436821
Agranulocytosis 58.04 16.76 57 14891 38172 64445612
Nephropathy toxic 55.62 16.76 40 14908 17474 64466310
Respiratory failure 55.30 16.76 118 14830 161065 64322719
Heparin-induced thrombocytopenia 53.76 16.76 30 14918 8449 64475335
Dizziness 52.85 16.76 17 14931 430146 64053638
Pancytopenia 51.57 16.76 107 14841 143202 64340582
Platelet count decreased 51.01 16.76 117 14831 167594 64316190
Leukopenia 50.61 16.76 87 14861 101155 64382629
Disseminated intravascular coagulation 50.54 16.76 49 14899 32299 64451485
Stevens-Johnson syndrome 50.02 16.76 50 14898 34199 64449585
Arthralgia 48.43 16.76 21 14927 442239 64041545
Transplant rejection 46.87 16.76 36 14912 17365 64466419
Renal tubular necrosis 45.32 16.76 39 14909 22071 64461713
Neutropenia 44.30 16.76 139 14809 239485 64244299
Headache 44.06 16.76 35 14913 529432 63954352
Toxic epidermal necrolysis 43.12 16.76 48 14900 37118 64446666
Clostridium difficile colitis 40.22 16.76 40 14908 27183 64456601
Acute generalised exanthematous pustulosis 39.88 16.76 30 14918 14028 64469756
Choroiditis 38.52 16.76 13 14935 1074 64482710
Dialysis 37.04 16.76 31 14917 16889 64466895
Rash 36.95 16.76 206 14742 458343 64025441
Fall 36.65 16.76 26 14922 416800 64066984
Joint swelling 35.89 16.76 4 14944 215378 64268406
Cholestasis 32.84 16.76 46 14902 44826 64438958
Autoimmune haemolytic anaemia 31.67 16.76 20 14928 7056 64476728
Toxic skin eruption 31.61 16.76 30 14918 19254 64464530
Blood creatinine increased 31.03 16.76 85 14863 135697 64348087
Weight increased 30.85 16.76 6 14942 213342 64270442
Acute respiratory distress syndrome 30.12 16.76 41 14907 38894 64444890
Hypotension 29.89 16.76 170 14778 380804 64102980
Dermatitis exfoliative generalised 29.73 16.76 18 14930 5898 64477886
Nasopharyngitis 29.46 16.76 5 14943 196068 64287716
Prothrombin time prolonged 28.73 16.76 26 14922 15715 64468069
Drug intolerance 27.79 16.76 5 14943 187987 64295797
Alopecia 27.79 16.76 3 14945 165687 64318097
Haemodialysis 26.92 16.76 26 14922 17051 64466733
Linear IgA disease 26.74 16.76 13 14935 2761 64481023
Systemic candida 26.23 16.76 16 14932 5313 64478471
Nephritis 26.16 16.76 14 14934 3632 64480152
Blood bilirubin increased 25.57 16.76 47 14901 57506 64426278
Anaphylactic reaction 25.53 16.76 52 14896 68612 64415172
Haemoglobin decreased 25.50 16.76 101 14847 194962 64288822
Enterococcal infection 25.49 16.76 23 14925 13843 64469941
Acinetobacter infection 25.28 16.76 12 14936 2417 64481367
Interstitial lung disease 25.19 16.76 64 14884 97668 64386116
Blood alkaline phosphatase increased 25.06 16.76 46 14902 56233 64427551
Renal impairment 24.61 16.76 78 14870 134939 64348845
Aspartate aminotransferase increased 24.44 16.76 72 14876 119716 64364068
Subclavian artery occlusion 24.37 16.76 6 14942 159 64483625
Rash morbilliform 24.19 16.76 15 14933 5126 64478658
Neutrophil count decreased 23.59 16.76 54 14894 77142 64406642
Weight decreased 23.57 16.76 19 14929 285720 64198064
White blood cell count decreased 23.33 16.76 85 14863 157752 64326032
Respiratory distress 22.33 16.76 42 14906 52289 64431495
Pseudomembranous colitis 22.27 16.76 14 14934 4902 64478882
Rash erythematous 21.96 16.76 40 14908 48593 64435191
Pain in extremity 21.64 16.76 23 14925 303062 64180722
Petechiae 21.50 16.76 24 14924 18602 64465182
Alanine aminotransferase increased 21.50 16.76 76 14872 138955 64344829
Febrile neutropenia 21.26 16.76 93 14855 187564 64296220
Neutrophilic dermatosis 21.11 16.76 7 14941 548 64483236
Abdominal discomfort 20.98 16.76 8 14940 182314 64301470
Staphylococcal infection 20.79 16.76 40 14908 50638 64433146
Dermatitis exfoliative 20.68 16.76 18 14930 10334 64473450
Hepatic failure 20.65 16.76 42 14906 55352 64428432
Pseudomonas infection 20.57 16.76 23 14925 17860 64465924
Antibiotic level above therapeutic 20.43 16.76 7 14941 606 64483178
Aplasia pure red cell 19.97 16.76 15 14933 6999 64476785
Hepatic cytolysis 19.57 16.76 20 14928 14029 64469755
International normalised ratio increased 19.52 16.76 51 14897 79116 64404668
Pleural effusion 19.41 16.76 69 14879 126490 64357294
Extravasation blood 19.28 16.76 6 14942 383 64483401
Acanthosis 19.03 16.76 6 14942 400 64483384
White blood cell count increased 18.88 16.76 45 14903 65969 64417815
Aspergillus infection 18.73 16.76 21 14927 16358 64467426
Spontaneous haematoma 18.71 16.76 8 14940 1263 64482521
Hepatic function abnormal 18.56 16.76 44 14904 64269 64419515
Drug abuse 18.55 16.76 4 14944 132370 64351414
Blood culture positive 18.44 16.76 15 14933 7853 64475931
Muscle spasms 18.32 16.76 5 14943 141018 64342766
Leukocytosis 18.27 16.76 32 14916 37708 64446076
Organ failure 18.11 16.76 11 14937 3622 64480162
Clostridium difficile infection 17.95 16.76 31 14917 36132 64447652
Purpura 17.85 16.76 21 14927 17225 64466559
Insomnia 17.80 16.76 12 14936 197824 64285960
Skin oedema 17.71 16.76 8 14940 1440 64482344
Neuralgic amyotrophy 17.55 16.76 5 14943 235 64483549
Moraxella infection 17.48 16.76 6 14942 522 64483262
Haemolytic anaemia 17.37 16.76 20 14928 16033 64467751
Contusion 16.91 16.76 3 14945 113962 64369822
Klebsiella infection 16.88 16.76 18 14930 13263 64470521

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J01CG02 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
BETA-LACTAM ANTIBACTERIALS, PENICILLINS
Beta-lactamase inhibitors
FDA MoA N0000000202 beta Lactamase Inhibitors
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents
MeSH PA D065093 beta-Lactamase Inhibitors
MeSH PA D004791 Enzyme Inhibitors
CHEBI has role CHEBI:33281 antibiotics
CHEBI has role CHEBI:35441 antiinfective agents
CHEBI has role CHEBI:35625 beta-lactamase inhibitors
FDA EPC N0000175930 beta Lactamase Inhibitor

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Infection of skin AND/OR subcutaneous tissue indication 19824006
Abscess of liver indication 27916005
Peritonitis indication 48661000
Bacterial pneumonia indication 53084003 DOID:874
Haemophilus influenzae pneumonia indication 70036007
Appendicitis indication 74400008 DOID:8337
Abdominal abscess indication 75100008
Cholecystitis indication 76581006 DOID:1949
Infection due to Staphylococcus aureus indication 406602003
Bacterial cystitis indication 424551004
Nosocomial pneumonia indication 425464007
Sepsis caused by Haemophilus influenzae indication 447685007
Sepsis caused by Serratia indication 449084002
Bacterial pyelonephritis indication 838353009
Complicated Skin and Skin Structure Staphylococcus Aureus Infection indication
E. Coli Complicated Appendicitis indication
Staphylococcus Nosocomial Pneumonia indication
Diabetic Foot Infection indication
Bacteroides Peritonitis indication
E. Coli Endometritis indication
E. Coli Appendicitis indication
Inflammatory Disease of Female Pelvic Organs indication
E. Coli Pelvic Inflammatory Disease indication
Bacteroides Complicated Appendicitis indication
Bacteroides Appendicitis indication
Complicated Skin and Skin Structure Infection indication
E. Coli Peritonitis indication
Ecthyma gangrenosum off-label use 17732003
Infection of bone off-label use 111253001
Sepsis of the newborn off-label use 206376005
Diverticulitis of gastrointestinal tract off-label use 271366000
Pseudomonas Respiratory Tract Infection in Cystic Fibrosis off-label use
Blood coagulation disorder contraindication 64779008 DOID:1247
Kidney disease contraindication 90708001 DOID:557
Infectious mononucleosis contraindication 271558008 DOID:8568
Neutropenic disorder contraindication 303011007 DOID:1227
Pseudomembranous enterocolitis contraindication 397683000




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.19 acidic
pKa2 0.39 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ZOSYN WYETH PHARMS N050684 Oct. 22, 1993 DISCN INJECTABLE INJECTION 6900184 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ZOSYN WYETH PHARMS N050684 Oct. 22, 1993 DISCN INJECTABLE INJECTION 8133883 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ZOSYN WYETH PHARMS N050684 Oct. 22, 1993 DISCN INJECTABLE INJECTION 6900184 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ZOSYN WYETH PHARMS N050684 Oct. 22, 1993 DISCN INJECTABLE INJECTION 8133883 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ZOSYN WYETH PHARMS N050684 Oct. 22, 1993 DISCN INJECTABLE INJECTION 6900184 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ZOSYN WYETH PHARMS N050684 Oct. 22, 1993 DISCN INJECTABLE INJECTION 8133883 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ZOSYN WYETH PHARMS N050684 Oct. 22, 1993 DISCN INJECTABLE INJECTION 6900184 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ZOSYN WYETH PHARMS N050684 Oct. 22, 1993 DISCN INJECTABLE INJECTION 8133883 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 40MG BASE/ML;EQ 5MG BASE/ML ZOSYN IN PLASTIC CONTAINER WYETH PHARMS N050750 Feb. 24, 1998 RX INJECTABLE INJECTION 6900184 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 40MG BASE/ML;EQ 5MG BASE/ML ZOSYN IN PLASTIC CONTAINER WYETH PHARMS N050750 Feb. 24, 1998 RX INJECTABLE INJECTION 8133883 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 4GM BASE/100ML;EQ 500MG BASE/100ML ZOSYN IN PLASTIC CONTAINER WYETH PHARMS N050750 Feb. 24, 1998 RX INJECTABLE INJECTION 6900184 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 4GM BASE/100ML;EQ 500MG BASE/100ML ZOSYN IN PLASTIC CONTAINER WYETH PHARMS N050750 Feb. 24, 1998 RX INJECTABLE INJECTION 8133883 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 60MG BASE/ML;EQ 7.5MG BASE/ML ZOSYN IN PLASTIC CONTAINER WYETH PHARMS N050750 Feb. 24, 1998 RX INJECTABLE INJECTION 6900184 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 60MG BASE/ML;EQ 7.5MG BASE/ML ZOSYN IN PLASTIC CONTAINER WYETH PHARMS N050750 Feb. 24, 1998 RX INJECTABLE INJECTION 8133883 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 7129232 May 15, 2028 COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI), USED IN COMBINATION WITH METRONIDAZOLE, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OF AGE)
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 7129232 May 15, 2028 COMPLICATED URINARY TRACT INFECTIONS (CUTI), INCLUDING PYELONEPHRITIS, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OLD)
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 7129232 May 15, 2028 METHODS FOR TREATING BACTERIAL INFECTIONS
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 7129232 May 15, 2028 METHODS OF TREATING BACTERIAL ILLNESSES
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 10028963 Sept. 7, 2032 TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 10028963 Sept. 7, 2032 TREATMENT OF VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 9724353 Sept. 7, 2032 TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 9724353 Sept. 7, 2032 TREATMENT OF VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 8685957 Sept. 27, 2032 METHODS OF TREATING BACTERIAL ILLNESSES
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 10420841 March 14, 2034 COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI), USED IN COMBINATION WITH METRONIDAZOLE, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OF AGE)
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 10420841 March 14, 2034 COMPLICATED URINARY TRACT INFECTIONS (CUTI), INCLUDING PYELONEPHRITIS, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OLD)
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 10420841 March 14, 2034 TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTION
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 10420841 March 14, 2034 TREATMENT OF COMPLICATED URINARY TRACT INFECTION
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 11278622 March 14, 2034 TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA (HABP)
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 11278622 March 14, 2034 TREATMENT OF VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (VABP)
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 8968753 March 14, 2034 COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI), USED IN COMBINATION WITH METRONIDAZOLE, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OF AGE)
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 8968753 March 14, 2034 COMPLICATED URINARY TRACT INFECTIONS (CUTI), INCLUDING PYELONEPHRITIS, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OLD)
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 8968753 March 14, 2034 TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTION
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 8968753 March 14, 2034 TREATMENT OF COMPLICATED URINARY TRACT INFECTION, INCLUDING PYELONEPHRITIS
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 10376496 Sept. 9, 2034 TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTION IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 10376496 Sept. 9, 2034 TREATMENT OF COMPLICATED URINARY TRACT INFECTION IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 10933053 Sept. 9, 2034 TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 10933053 Sept. 9, 2034 TREATMENT OF VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS Dec. 19, 2019 NEW CHEMICAL ENTITY
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS Dec. 19, 2024 GENERATING ANTIBIOTIC INCENTIVES NOW
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS April 21, 2025 NEW PATIENT POPULATION

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Beta-lactamase TEM Enzyme INHIBITOR IC50 6.60 WOMBAT-PK CHEMBL
Beta-lactamase Enzyme IC50 6.53 WOMBAT-PK
Beta-lactamase Enzyme IC50 7.82 WOMBAT-PK
Beta-lactamase Enzyme IC50 5.47 CHEMBL
Beta-lactamase SHV-1 Enzyme IC50 6.65 CHEMBL
Beta-lactamase 1 Enzyme IC50 6.52 DRUG MATRIX
IMI-1; IMI-1 carbapenemase Enzyme IC50 7.52 CHEMBL
Beta-lactamase Enzyme IC50 7 CHEMBL
Beta-lactamase Enzyme IC50 7.22 CHEMBL
Beta-lactamase Enzyme IC50 6.09 CHEMBL
Beta-lactamase Enzyme IC50 6.72 CHEMBL
Beta-lactamase Enzyme IC50 6.03 CHEMBL
Beta-lactamase Enzyme IC50 7.40 CHEMBL
Beta-lactamase Enzyme IC50 8 CHEMBL
Beta-lactamase Enzyme IC50 8.40 CHEMBL
Carbapenem-hydrolizing beta-lactamase SFC-1 Enzyme IC50 5.16 CHEMBL
Carbepenem-hydrolyzing beta-lactamase KPC Enzyme Ki 4.13 CHEMBL
Beta-lactamase Enzyme IC50 7.02 CHEMBL
Beta-lactamase Enzyme IC50 8.70 CHEMBL
Beta-lactamase SHV-1 Enzyme IC50 6.96 CHEMBL
Beta-lactamase Enzyme IC50 6.62 CHEMBL
Beta-lactamase GES-13 Enzyme IC50 7.22 CHEMBL
Beta-lactamase Enzyme IC50 7.10 CHEMBL
Class D beta-lactamase Unclassified IC50 6.80 CHEMBL
Beta-lactamase Enzyme IC50 6.30 CHEMBL
Beta-lactamase Enzyme IC50 8.66 CHEMBL
Beta-lactamase Enzyme IC50 5.70 CHEMBL
Beta-lactamase Enzyme IC50 5.70 CHEMBL
Beta-lactamase Enzyme IC50 6.29 CHEMBL
Beta-lactamase Enzyme IC50 7.40 CHEMBL

External reference:

IDSource
D00660 KEGG_DRUG
89785-84-2 SECONDARY_CAS_RN
4020843 VANDF
C0075870 UMLSCUI
CHEBI:9421 CHEBI
TAZ PDB_CHEM_ID
CHEMBL404 ChEMBL_ID
DB01606 DRUGBANK_ID
CHEMBL1439 ChEMBL_ID
D000078142 MESH_DESCRIPTOR_UI
123630 PUBCHEM_CID
10789 IUPHAR_LIGAND_ID
6340 INN_ID
SE10G96M8W UNII
221167 RXNORM
30782 MMSL
5543 MMSL
d04404 MMSL
004398 NDDF
004399 NDDF
410931003 SNOMEDCT_US
427652008 SNOMEDCT_US
96007008 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Zosyn in Galaxy Containers HUMAN PRESCRIPTION DRUG LABEL 2 0206-8860 INJECTION, SOLUTION 250 mg INTRAVENOUS NDA 27 sections
Zosyn in Galaxy Containers HUMAN PRESCRIPTION DRUG LABEL 2 0206-8860 INJECTION, SOLUTION 250 mg INTRAVENOUS NDA 27 sections
Zosyn in Galaxy Containers HUMAN PRESCRIPTION DRUG LABEL 2 0206-8861 INJECTION, SOLUTION 375 mg INTRAVENOUS NDA 27 sections
Zosyn in Galaxy Containers HUMAN PRESCRIPTION DRUG LABEL 2 0206-8861 INJECTION, SOLUTION 375 mg INTRAVENOUS NDA 27 sections
Zosyn in Galaxy Containers HUMAN PRESCRIPTION DRUG LABEL 2 0206-8862 INJECTION, SOLUTION 500 mg INTRAVENOUS NDA 27 sections
Zosyn in Galaxy Containers HUMAN PRESCRIPTION DRUG LABEL 2 0206-8862 INJECTION, SOLUTION 500 mg INTRAVENOUS NDA 27 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0409-2999 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 1.50 g INTRAVENOUS ANDA 25 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0409-3374 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 0.25 g INTRAVENOUS ANDA 25 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0409-3378 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 0.38 g INTRAVENOUS ANDA 25 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0409-3379 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 0.50 g INTRAVENOUS ANDA 25 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0409-3383 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 0.25 g INTRAVENOUS ANDA 26 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0409-3385 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 0.38 g INTRAVENOUS ANDA 26 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0409-3390 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 0.50 g INTRAVENOUS ANDA 26 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0781-3110 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 0.25 g INTRAVENOUS ANDA 26 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0781-3113 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 0.38 g INTRAVENOUS ANDA 26 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0781-3114 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 0.50 g INTRAVENOUS ANDA 26 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0781-3117 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 1.50 g INTRAVENOUS ANDA 26 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0781-3180 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 4.50 g INTRAVENOUS ANDA 26 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0781-9210 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 0.25 g INTRAVENOUS ANDA 26 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0781-9213 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 0.38 g INTRAVENOUS ANDA 26 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0781-9214 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 0.50 g INTRAVENOUS ANDA 26 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 22607-012 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 0.50 g INTRAVENOUS ANDA 26 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 22607-034 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 0.25 g INTRAVENOUS ANDA 26 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 22607-056 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 0.38 g INTRAVENOUS ANDA 26 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 22607-679 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 4.50 g INTRAVENOUS ANDA 26 sections
Piperacillin, Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 25021-164 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 0.25 g INTRAVENOUS ANDA 30 sections
Piperacillin, Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 25021-165 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 0.38 g INTRAVENOUS ANDA 30 sections
Piperacillin, Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 25021-166 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 0.50 g INTRAVENOUS ANDA 30 sections
Piperacillin, Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 25021-175 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 0.25 g INTRAVENOUS ANDA 30 sections
Piperacillin, Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 25021-176 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 0.38 g INTRAVENOUS ANDA 30 sections